search

Active clinical trials for "Macular Degeneration"

Results 111-120 of 1337

Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

Non-exudative Age-related Macular DegenerationDiabetic Retinopathy3 more

This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.

Active13 enrollment criteria

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration...

Age-Related Macular Degeneration

The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.

Active25 enrollment criteria

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Stargardt Disease 1

To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).

Active14 enrollment criteria

Phase 3 Study of ALK-001 in Geographic Atrophy

Geographic AtrophyAge Related Macular Degeneration3 more

This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.

Active4 enrollment criteria

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)

Neovascular (Wet) AMD

This is a randomized, double-masked, parallel-group, multicenter, therapeutic equivalence study evaluating the efficacy, safety, and immunogenicity of AVT06 compared with Eylea in subjects with neovascular (wet) AMD.

Active8 enrollment criteria

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration...

Geographic Atrophy

This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.

Active15 enrollment criteria

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration...

Neovascular Age-Related Macular Degeneration

Evaluate the safety, tolerability, and efficacy of OTX-TKI for intravitreal use in subjects with Neovascular Age-Related Macular Degeneration

Active8 enrollment criteria

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related...

Age-related Macular Degeneration

The purpose of this study is to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received anti-VEGF (vascular endothelial growth factor) treatment.

Active14 enrollment criteria

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)...

Neovascular Age-related Macular DegenerationWet Macular Degeneration1 more

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (nAMD) also referred to as Wet AMD. Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. The purpose of this phase 2, open label study is to evaluate whether different doses of RGX-314 from two different formulations (clinical versus eventual commercial formulation) perform the same in humans when delivered by subretinal administration

Active13 enrollment criteria

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients...

Neovascular Age-related Macular Degeneration

The purpose of this phase IV study is to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration (wAMD) with the purpose to evaluate their potential in supporting the treatment regimen choice (q12w or q8w).

Active11 enrollment criteria
1...111213...134

Need Help? Contact our team!


We'll reach out to this number within 24 hrs